Exact Sciences(EXAS)
(EXAS)
Kvartalsrapport (Q4)
37 dager siden‧1t 1min
Ordredybde
Stengt
Antall
Kjøp
0
Selg
Antall
0
Siste handler
Tid | Pris | Antall | Kjøpere | Selger |
---|---|---|---|---|
- | - | - | - |
Volumvektet snittpris (VWAP)
-Volumvektet snittpris (VWAP)
-Omsetning (USD)
382 445 574Meglerstatistikk
Fant ingen data
Selskapshendelser
Kommende | |
---|---|
Selskapskalender ikke tilgjengelig |
Historisk | ||
---|---|---|
2023 Kvartalsrapport (Q4) | 21. feb. | |
2023 Årsrapport | 21. feb. | |
2023 Kvartalsrapport (Q3) | 1. nov. 2023 | |
2023 Kvartalsrapport (Q2) | 1. aug. 2023 | |
2023 Generalforsamling | 8. juni 2023 |
Data hentes fra Morningstar, Quartr
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Kvartalsrapport (Q4)
37 dager siden‧1t 1min
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
Kommende | |
---|---|
Selskapskalender ikke tilgjengelig |
Historisk | ||
---|---|---|
2023 Kvartalsrapport (Q4) | 21. feb. | |
2023 Årsrapport | 21. feb. | |
2023 Kvartalsrapport (Q3) | 1. nov. 2023 | |
2023 Kvartalsrapport (Q2) | 1. aug. 2023 | |
2023 Generalforsamling | 8. juni 2023 |
Data hentes fra Morningstar, Quartr
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- for 17 t sidenfor 17 t sidenExact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire
- 19. nov. 2023 · Endret19. nov. 2023 · EndretProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5. nov. 20235. nov. 2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
- 23. juni 202323. juni 2023"Exact Sciences (EXAS) could eventually nab half of the colon cancer screening market, an analyst said after the company's next-generation Cologuard beat the original product in a study of 20,000 people." https://www.investors.com/news/technology/exas-stock-has-surged-since-october-why-this-news-could-stoke-it-again/?src=A00220
- Brøt denne akkurat ut av den fallende trenden nå?
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Kvartalsrapport (Q4)
37 dager siden‧1t 1min
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- for 17 t sidenfor 17 t sidenExact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer. Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early. Source: Business Wire
- 19. nov. 2023 · Endret19. nov. 2023 · EndretProfitability Is Still Two Years Out. Today (Nov. 1, 2023), Exact Sciences is still reporting losses. But that's expected to change in 2025. At that point, analysts polled by FactSet expect the company to report an adjusted gain of 56 cents per share. Sales in 2023-25 are expected to grow 13%-15%. EXAS stock also has a nearly perfect Relative Strength Rating of 98. This puts shares in the top 2% of all stocks in terms of 12-month performance, according to IBD Digital. Shares also have a strong Composite Rating of 95, meaning EXAS stock outranks 95% of all stocks when it comes to fundamental and technical measures. Source: https://www.investors.com/news/technology/exas-stock-why-this-top-stock-is-on-an-eight-month-hot-streak/
- 5. nov. 20235. nov. 2023WHY EXAS COULD SOON BECOME PROFITABLE. "Looking forward, it remains to be seen if the robust Cologuard business momentum will continue or if the company's rising expenditures will pressure (or limit) margins in the near term," Canaccord's Mikson said. He kept his buy rating and 120 price target on EXAS stock. This is the first quarter since March 2021 that Exact Sciences hasn't reported an adjusted loss. Sales climbed 20% year over year. In the September quarter, sales in Exact Sciences' screening division surged 31% to $472 million. That beat EXAS stock analysts' view by $10 million, according to FactSet. The screening segment includes primarily laboratory service revenue from Cologuard and blood-based genetic tests that screen for hereditary forms of cancer called PreventionGenetics. "The solid results were driven by continued Cologuard volume growth, with revenue from this product increasing roughly 30% year over year," Canaccord Genuity analyst Kyle Mikson said in a report to clients. Source: https://www.investors.com/news/technology/exas-stock-why-this-large-cathie-wood-holding-could-soon-be-profitable/
- 23. juni 202323. juni 2023"Exact Sciences (EXAS) could eventually nab half of the colon cancer screening market, an analyst said after the company's next-generation Cologuard beat the original product in a study of 20,000 people." https://www.investors.com/news/technology/exas-stock-has-surged-since-october-why-this-news-could-stoke-it-again/?src=A00220
- Brøt denne akkurat ut av den fallende trenden nå?
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Stengt
Antall
Kjøp
0
Selg
Antall
0
Siste handler
Tid | Pris | Antall | Kjøpere | Selger |
---|---|---|---|---|
- | - | - | - |
Volumvektet snittpris (VWAP)
-Volumvektet snittpris (VWAP)
-Omsetning (USD)
382 445 574Meglerstatistikk
Fant ingen data
Selskapshendelser
Kommende | |
---|---|
Selskapskalender ikke tilgjengelig |
Historisk | ||
---|---|---|
2023 Kvartalsrapport (Q4) | 21. feb. | |
2023 Årsrapport | 21. feb. | |
2023 Kvartalsrapport (Q3) | 1. nov. 2023 | |
2023 Kvartalsrapport (Q2) | 1. aug. 2023 | |
2023 Generalforsamling | 8. juni 2023 |
Data hentes fra Morningstar, Quartr